Amylin Pharmaceuticals LLC  

(Public, NASDAQ:AMLN)   Watch this stock  
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.36
Shares 164.28M
Beta     -
Inst. own 87%

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin -43.83% -83.51%
Operating margin -17.64% -75.53%
EBITD margin - 0.11%
Return on average assets -14.86% -31.95%
Return on average equity - -530.82%
Employees 1,300 -
CDP Score - -

Address

9360 Towne Centre Drive
SAN DIEGO, CA 92121
United States - Map
+1-858-5522200 (Phone)
+1-858-5522212 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.